Latest Intelligence in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
CommentWire
CommentWire

Abbott: 3,000 jobs axed as synergies with Solvay are realized

Following the acquisition of Solvay, Abbott Laboratories plans to lay-off 3,000 global workers. The job cuts are part of Abbott's drive to achieve long-term goals and improve efficiencies, while at the same time increasing sales and per-share earnings. The company's broader strategy is to increase access to emerging markets and diversify its products in the hope of increasing industry growth.

Published By Datamonitor
22 Sep 2010
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
CommentWire
CommentWire

Acergy and Subsea 7: deal signals a new reality in the oil and gas market

The planned merger between Acergy and Subsea 7, like the similar deal agreed by Schlumberger and Smith International earlier this year, illustrates the new environment in the oil and gas services market. With firms looking to become stronger so that they can overcome costs and complexity challenges, consolidation is likely to emerge as a popular strategy.

Published By Datamonitor
06 Jul 2010
CommentWire
CommentWire

Ache: Brazilian domestic player to step up its game

Ache, the Brazilian branded generics specialist, has announced its intention to pursue an initial public offering in order to raise capital and remain competitive. The move reflects the growing interest in Brazil's burgeoning pharmaceutical market, and is essential if Ache is to compete with the considerable growth in both domestic and international players in the country.

Published By Datamonitor
17 Nov 2010
Expert View
Expert View

ACR 2009: Benlysta outshines disappointing rheumatoid arthritis data

Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.

Published By Datamonitor
23 Oct 2009
CommentWire
CommentWire

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor
28 Jan 2011
ResearchWire
ResearchWire

Acute stroke: AstraZeneca drug candidate offers blockbuster potential

Published By Datamonitor
31 Aug 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.